About a million people have already been immunized with the experimental coronavirus vaccine of the Chinese company Sinopharm, which is still at the stage of clinical trials, the head of the company, Liu Jingzhen, said.
"In the mode of emergency use, the vaccine was applied to approximately one million people, not a single case of serious side effects was identified. People showed only mild symptoms," the South China Morning Post quoted Liu Jingzhen as saying.
In addition, the authorities of the Chinese province of Zhejiang reported that they made the Sinovac Biotec coronavirus vaccine available for emergency use in the province among high-risk groups. At the same time, it is not known exactly how many people received the vaccine.
On November 18, it was reported that according to preliminary test results, Sinovac's experimental CoronaVac vaccine causes a rapid immune response, but the level of antibodies produced by it is significantly lower than in people who have contracted the coronavirus. At the moment, the vaccine is in the third - final - stage of clinical trials.
In China, a division of the state-owned pharmaceutical company China National Pharmaceutical Group (Sinopharm) and the US-registered Sinovac Biotech are developing three vaccines as part of the state program. They were approved for use in emergency situations within the framework of clinical trials.
